CSI Market
Sign In | Register

Anika Therapeutics Inc (ANIK) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ANIK Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Anika Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-1.75
Depreciation & amortization2.91
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived2.30
Provision For Loan Losses Expensed0.23
Inventories Decrease /-Increase14.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.08
Share-based Compensation8.47
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Impairment Of Intangible Assets Excluding Goodwill-
Finance Lease Right Of Use Asset Amortization-
Investment Income Amortization Of Discount-
Amortization Of Acquisition Related Inventory Step Up-
Finance Lease Interest Payment On Liability-
Provision For Doubtful Accounts Net Of Recoveries-0.02
Increase Decrease In Lease Liabilities-0.47
Amortization Of Acquisition Related Intangible Assets-
Increase Decrease In Contingent Consideration-
Increase Decrease In Operating Lease Liability-
Interest Income On Acquired Note Receivable-0.18
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable5.41
Increase (Decrease) in Accounts Payable0.17
Increase (Decrease) in Accrued Liabilities-1.07
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.83
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-37.11
Discontinued operations0.00
Net Cash flow from Operating Activities-5.53
Investing Activities
Capital Expenditures-2.88
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Proceeds from Sale of Notes Receivable0.36
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-2.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-9.33
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-1.72
Other net0.00
Finance Lease Principal Payments-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations57.48
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-11.05
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.41
Total Cash Flow-19.07
4 historic quarters locked

Sign in to unlock the full Anika Therapeutics Inc cash flow history.

Sign In Create Free Account

About Anika Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001171843-26-005012

Figures are derived from filed reports and may be restated. Historical data is subject to revision.